ReviewAtherosclerosis in psoriatic arthritis☆
Introduction
Atherosclerosis is accelerated in many autoimmune rheumatic diseases [1], [2], [3], [4], [5], [6], and the relative risk of coronary artery disease is 1.6 in patients with ankylosing spondylitis and psoriatic arthritis (PsA), 3.0 in individuals with rheumatoid arthritis (RA), and 6.0 in subjects with systemic lupus erythematosus (SLE) [7], [8]. However, the reason why atherosclerosis is accelerated in immune-inflammatory diseases has not been completely elucidated.
One of the most recent advances in understanding the pathogenesis of atherosclerosis is the recognition of the inflammatory nature of atherosclerotic lesions. Inflammatory mechanisms have been demonstrated in all stages of atherogenesis including induction, progression, and rupture of plaques.
Section snippets
Pathogenesis of atherosclerosis
The first step in atherogenesis is endothelial cell activation, a process which involves both traditional and non-traditional risk factors. Once activated, endothelial cells exhibit a pro-inflammatory phenotype characterized by an increased expression of adhesion molecules, which in turn promote the rolling and sticking of monocytes to the endothelial cell membrane [9], [10], [11]. The endothelial wall becomes more permeable allowing low-density lipoproteins (LDLs) to pass from the circulation
Immuno-inflammatory players in atherogenesis
Various molecules, as well as inflammatory and immune cells, have been shown to play an important role in the amplification loop of the inflammatory process promoting the activation of endothelial cells, smooth muscle cells, and macrophages [12].
Psoriatic arthritis: an immuno-inflammatory disease
PsA is defined as an axial and/or peripheral inflammatory arthritis associated with psoriasis. It is recognized as a disease entity distinct from RA and characterized by distal inter-phalangeal joint involvement, asymmetric distribution of arthritis, dactylitis, enthesitis, spinal involvement, and frequent association with HLA-B27. Interestingly, it has recently been suggested that PsA could be a multisystem disease involving even coronary arteries and the heart [41]. The pathogenesis of PsA is
Atherosclerosis and psoriatic arthritis
The risk of atherosclerosis in PsA patients could be increased by the chronic inflammatory state, due to an imbalanced secretion of pro-and anti-inflammatory cytokines.
Both PsA and atherosclerosis are mainly mediated by Th1 cells [9]. In fact, both diseases have a common pattern of T cell activation, including an increased percentage of cells expressing a Th1 cytokine profile (TNF-α, IL-1β, IL-10 and IFN) [9], [43].
The perturbation of angiogenesis appears to be an early pathogenetic event in
Conclusions
While rheumatic diseases have generally been regarded as non-fatal, the natural history of most of them is characterized by premature death due to cardiovascular disease. Even in patients with PsA, inflammatory mediators have been found in atherosclerotic plaques. This suggests that chronic inflammation acts independently and/or synergistically with the traditional risk factors in the pathogenesis of atherosclerosis. Moreover, with respect to other inflammatory rheumatic diseases, PsA patients
Take-home messages
- •
PsA, is associated with an increased prevalence of cardiovascular events due to accelerated atherosclerosis.
- •
In PsA atherosclerosis seems to depend on traditional and non-traditional risk factors, including immune-inflammatory biomarkers.
- •
Preclinical stages of atherosclerosis can be detected with non-invasive methods, such as carotid ultrasound.
References (64)
Cardiovascular risk in rheumatoid arthritis
Autoimmun Rev
(2009)- et al.
Cardiovascular involvement in systemic autoimmune diseases
Autoimmun Rev
(2009) - et al.
Cardiac involvement in systemic rheumatic diseases: an update
Autoimmun Rev
(2010) - et al.
Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality
Autoimmun Rev
(2011) - et al.
Endothelial dysfunction and vascular stiffness in systemic lupus erythematosus: are they early markers of subclinical atherosclerosis?
Autoimmun Rev
(2010) - et al.
From endothelial dysfunction to atherosclerosis
Autoimmun Rev
(2010) - et al.
How early is the atherosclerotic risk in rheumatoid arthritis?
Autoimmun Rev
(2010) - et al.
OxLDL/β2GPI-anti-oxLDL/β2GPI complex and atherosclerosis in SLE patients
Autoimmun Rev
(2007) - et al.
The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis
Autoimmun Rev
(2009) - et al.
Heat-shock proteins can promote as well as regulate autoimmunity
Autoimmun Rev
(2009)
Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis
Lancet
Cellular and humoral immune responses to heat shock protein 65 are both involved in promoting fatty-streak formation in LDL-receptor deficient mice
J Am Coll Cardiol
Interleukin-6 as a key player in systemic inflammation and joint destruction
Autoimmun Rev
Interleukin 23: a key cytokine in chronic inflammatory diseases
Joint Bone Spine
Abu El-Saad AM, Krieger T, Conrad K, et al. Interleukin-17-producing T helper cells in autoimmunity
Autoimmun Rev
Interleukin 17: an unlikely marker of acute coronary syndrome?
Atherosclerosis
Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis
Semin Arthritis Rheum
Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis
Autoimmun Rev
Dyslipidemia and inflammation: an evolutionary conserved mechanism
Clin Nutr
Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment
Autoimmun Rev
Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis
Semin Arthritis Rheum
Accelerated atherosclerosis in autoimmune rheumatic diseases
Circulation
Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus
Ann Rheum Dis
Subclinical carotid atherosclerosis in patients with psoriatic arthritis
Arthritis Rheum
Atherosclerosis — an inflammatory disease
N Engl J Med
Pentraxins, anti-pentraxin antibodies, and atherosclerosis
Clin Rev Allergy Immunol
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease
N Engl J Med
Inflammation and accelerated atherosclerosis-basic mechanisms
Rheum Dis Clin N Am
Relationship between anti-phospholipid and anti-endothelial cell antibodies III: beta 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules
Clin Exp Rheumatol
Atherosclerosis in systemic lupus erythematosus
Autoimmunity
T-cell-mediated lysis of endothelial cells in acute coronary syndromes
Circulation
CD4+ CD28− T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients
Circulation
Cited by (80)
Benefits of tumor necrosis factor inhibitors for cardiovascular disease in ankylosing spondylitis
2022, International ImmunopharmacologyCitation Excerpt :Inflammation burden has also been observed in psoriatic arthritis (PsA), which is part of the same spondyloarthritis (SpA) family. Previous literature reported that atherosclerosis was accelerated in rheumatic diseases, which led to a relative risk of coronary artery disease (CAD) of 1.6 in AS and PsA patients and nearly 3.0 in patients with rheumatoid arthritis (RA) [7]. Although it was shown that atherosclerosis progressed after two years of tumor necrosis factor inhibitors (TNFi) treatment [8], it was found to decelerate in long-term follow-up of up to 5 years [9], which might be attributed to partial inflammation control
Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease
2019, Autoimmunity ReviewsActivated Mast Cells Mediate Low-Grade Inflammation in Type 2 Diabetes: Interleukin-37 Could Be Beneficial
2018, Canadian Journal of DiabetesCitation Excerpt :IL-1-stimulated MCs cause the release of IL-6 without degranulation (56). Cytokine IL-6 plays an important role in rheumatoid arthritis and in psoriasis, which may be associated with an increased risk for type 2 diabetes and vice versa (57). In experimental rodents, the inhibition of MAPK in Th17 cells increases IL-6 production, leading to insulin resistance and type 2 diabetes (58).
Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis
2018, Best Practice and Research: Clinical RheumatologyAnalysis of coronary computed tomography angiography-derived pericoronary fat attenuation index characteristics in the diagnostic assessment of patients with Takayasu arteritis
2023, Quantitative Imaging in Medicine and Surgery
- ☆
The authors declare no conflicts of interest.